Page last updated: 2024-12-11

thyronines

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Thyronines: A group of metabolites derived from THYROXINE and TRIIODOTHYRONINE via the peripheral enzymatic removal of iodines from the thyroxine nucleus. Thyronine is the thyroxine nucleus devoid of its four iodine atoms. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

thyronine : A tyrosine derivative where the phenolic hydrogen of tyrosine is substituted by 4-hydroxyphenyl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5461103
CHEBI ID30662
SCHEMBL ID285217
MeSH IDM0021493

Synonyms (36)

Synonym
o-(4-hydroxyphenyl)-l-tyrosine
l-thyronine
1596-67-4
thyronine
4-(4-hydroxyphenoxy)-l-phenylalanine
CHEBI:30662
NCGC00018260-01
thyronines
(2s)-2-amino-3-[4-(4-hydroxyphenoxy)phenyl]propanoic acid
NCGC00018260-03
e4qn8g00cv ,
unii-e4qn8g00cv
einecs 216-483-8
SCHEMBL285217
AM83591
KKCIOUWDFWQUBT-AWEZNQCLSA-N
l-tyrosine, o-(4-hydroxyphenyl)-
o-(4-hydroxyphenyl)tyrosine
thyronine, l-
desiodothyroxine
.beta.-(p-hydroxyphenoxy)phenylalanine
AKOS027384361
J-009627
mfcd00063070
beta-(p-hydroxyphenoxy)phenylalanine
b-(p-hydroxyphenoxy)phenylalanine
(s)-2-amino-3-(4-(4-hydroxyphenoxy)phenyl)propanoic acid
Q3052031
h-thy-oh
l-thyronine/ desiodothyroxine
MS-23877
(s)-2-amino-3-(4-(4-hydroxyphenoxy)phenyl)propanoicacid
DTXSID801318222
CS-0059515
HY-113082
3-[p-(p-hydroxyphenoxy)phenyl]-l-alanine

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Triiodothyronine (T(3)), formed chiefly by deiodination of T(4), is the active hormone at the nuclear receptor, and it is generally accepted that deiodination is the major pathway regulating T(3) bioavailability in mammalian tissues."( Alternate pathways of thyroid hormone metabolism.
Chopra, IJ; Green, WL; Hays, MT; Huang, WS; Wu, SY, 2005
)
0.33
" This dose showed systemic bioavailability (0."( 3-Iodothyronamine: a modulator of the hypothalamus-pancreas-thyroid axes in mice.
Bigagli, E; Chiellini, G; Cinci, L; De Siena, G; Dicembrini, I; Lodovici, M; Manni, ME; Marchini, M; Raimondi, L; Saba, A; Zucchi, R, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" Almost linear dose-response relationship was found between the dose of T4 and its biliary excretion up to the dose of 640 micrograms, only smaller increase being observed after 1280 micrograms T4."( Studies on in-vivo capacity of thyroxine deiodinating system in rat liver: biliary excretion of several iodothyronines after increasing loading doses of thyroxine.
Földes, O; Gschwendtová, K; Langer, P, 1987
)
0.49
" At the pharmacologically active dosage we used, the drug induced a moderate redistribution of ventricular isomyosins in favour of V, at the expense of V1."( Effect of amiodarone on myosin isoenzymic distribution in rat ventricular myocardium.
Bouveret, P; Gagnol, JP; Jungbluth, L; Mercadier, JJ; Nahum, D; Nokin, P; Schwartz, K; Wisnewsky, C, 1987
)
0.27
"1 mU (ip, daily for 3 days), and there was a linear dose-response thereafter."( Characterization of thyrotropin-induced increase in iodothyronine monodeiodinating activity in mice.
Florsheim, WH; Reggio, R; Wu, SY, 1985
)
0.27
" The dose-response curves of inhibition of the binding of [(125)I]rT(3) to antibody obtained by serial dilutions of serum extracts were essentially parallel to the standard assay curve."( A radioimmunoassay for measurement of 3,3',5'-triiodothyronine (reverse T3).
Chopra, IJ, 1974
)
0.25
"0 g/day for 7 days) dosing schedule were employed to achieve varying levels of deiodinase inhibition."( 3,5,3'-Triiodothyronine (T3) sulfate: a major metabolite in T3 metabolism in man.
LoPresti, JS; Nicoloff, JT, 1994
)
0.29
" In the dose-response studies, a biphasic increase in medium IGF-I was observed in both cells and limb bones, with peak stimulatory concentrations of 10(-8) M for T3 and 10(-7) M for T4 in both systems."( Thyroid hormones increase insulin-like growth factor I content in the medium of rat bone tissue.
Caplice, MD; Khanna, V; Lakatos, P; Stern, PH, 1993
)
0.29
" We treated 54 adult and seven pediatric patients suffering from severe low cardiac output in different clinical conditions with a mean bolus dosage of 2+/-1."( Thyronin treatment in adult and pediatric heart surgery: clinical experience and review of the literature.
Carrel, T; Eckstein, F; Englberger, L; Mohacsi, P; Mury, R, 2002
)
0.31
" The biphasic dose-response observed after either T1AM or T3 administration seems to indicate shared mechanisms and/or functions of sleep regulation in the preoptic region."( Effects of acute microinjections of the thyroid hormone derivative 3-iodothyronamine to the preoptic region of adult male rats on sleep, thermoregulation and motor activity.
James, TD; Martin, JV; Moffett, SX; Scanlan, TS, 2013
)
0.39
" Forty subjects were randomized at a 1:1 ratio to receive either TRC150094 dosed at 50 mg or placebo once daily for 4 weeks."( The effect of a diiodothyronine mimetic on insulin sensitivity in male cardiometabolic patients: a double-blind randomized controlled trial.
Ackermans, M; Chauthaiwale, V; Dutt, C; Hassing, C; Mohanan, A; Nederveen, A; Nieuwdorp, M; Pathak, K; Serlie, M; Stroes, E; Thakkar, P; van der Valk, F; Visser, M, 2014
)
0.4
" TRC150094 dosed 50 mg once daily was safe and well tolerated."( The effect of a diiodothyronine mimetic on insulin sensitivity in male cardiometabolic patients: a double-blind randomized controlled trial.
Ackermans, M; Chauthaiwale, V; Dutt, C; Hassing, C; Mohanan, A; Nederveen, A; Nieuwdorp, M; Pathak, K; Serlie, M; Stroes, E; Thakkar, P; van der Valk, F; Visser, M, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
thyronineA tyrosine derivative where the phenolic hydrogen of tyrosine is substituted by 4-hydroxyphenyl.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (941)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990698 (74.18)18.7374
1990's69 (7.33)18.2507
2000's54 (5.74)29.6817
2010's96 (10.20)24.3611
2020's24 (2.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 66.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index66.87 (24.57)
Research Supply Index6.89 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index122.93 (26.88)
Search Engine Supply Index2.11 (0.95)

This Compound (66.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (0.41%)5.53%
Reviews68 (6.97%)6.00%
Case Studies7 (0.72%)4.05%
Observational1 (0.10%)0.25%
Other896 (91.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]